Business ❯ Pharmaceutical Industry ❯ Drug Manufacturers

Pricing Strategies

Market Competition Market Access Market Agreements Market Regulations Market Impact Consumer Discounts Market Dynamics Direct-to-Consumer Sales Market Regulation Pharmacy Benefit Managers Direct-Pay Programs Most Favored Nation Pricing Price Adjustments Negotiations with Government Government Regulations Negotiation Tactics 340B Drug Pricing Program Rebate Systems Market Competition in Pharmaceuticals Market Reactions Market Trends Profit Margins International Agreements Counter Offers Discount Programs Legal Challenges Consumer Access Investment Commitments Rebates Discount Agreements Pfizer and Bristol-Myers Squibb Market Power Market Compliance

White House Projects $529 Billion in Savings From Trump’s MFN Drug Pricing Plan

Lawmakers question secret deals that rely on other countries paying more for drugs.

Lawmakers Seek Transparency as TrumpRx Faces Questions on Who Saves

TrumpRx Debuts With 43 Discounted Brand Drugs as Analyses Flag Cheaper Generics and Limits

Oregon Sues Insulin Makers and PBMs, Alleging $900 Million Pricing Scheme

Drugmakers to Lift 2026 U.S. List Prices on 350 Branded Medicines

Trump Adds Nine Pharma Giants to Drug Pricing Deals, Reaching 14 Signatories as TrumpRx Nears Launch

Medicare’s First Negotiated Drug Prices Take Effect Jan. 1, Cutting 2026 Costs

White House Finalizes GLP-1 Price Deal With Lilly and Novo, Setting $50 Medicare Copays

RFK Jr. To Announce New HHS Plan To Cut U.S. Drug Prices Today

Trump Gives Pharma CEOs 60 Days to Adopt Most-Favored-Nation Drug Pricing

Bristol Myers Squibb and Pfizer to Offer Eliquis at 40% Cash-Price Discount